Treating latent autoimmune diabetes in adults in the era of cardiovascular outcomes trials: Old dog should learn new tricks
T Koufakis, P Vas, K Kotsa - Diabetic Medicine, 2021 - Wiley Online Library
Background Latent autoimmune diabetes in adults (LADA) is characterised by
pathophysiological and clinical heterogeneity. Hence, the optimal treatment strategy for this …
pathophysiological and clinical heterogeneity. Hence, the optimal treatment strategy for this …
Prevalence and clinical characteristics of adults presenting with sodium-glucose cotransporter-2 inhibitor-associated diabetic ketoacidosis at a Canadian Academic …
A Clark, AS Mohammed, A Raut, S Moore… - Canadian Journal of …, 2021 - Elsevier
Objectives In this study, we examined the prevalence and clinical characteristics of sodium-
glucose cotransporter-2 inhibitor (SGLT2i)-associated diabetes ketoacidosis (DKA) …
glucose cotransporter-2 inhibitor (SGLT2i)-associated diabetes ketoacidosis (DKA) …
[PDF][PDF] Latent Autoimmune Diabetes in Adults (LADA)-Clinical Features
YM Song - 內科學誌, 2021 - tsim.org.tw
Among the spectrum of different types of diabetes mellitus (DM), latent autoimmune diabetes
in adults (LADA) distinguishes itself from the more prevalent type 2 DM (T2DM) by a …
in adults (LADA) distinguishes itself from the more prevalent type 2 DM (T2DM) by a …